Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) will announce its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and recent developments. Interested participants can access the call via a pre-registration link. Geron focuses on developing imetelstat, a telomerase inhibitor, currently being tested in two Phase 3 trials: IMerge for lower-risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis. More details are available on their website.

Positive

• Ongoing development of imetelstat, which targets hematologic malignancies.
• Conducting two Phase 3 clinical trials, potentially expanding treatment options.

Negative

• None.

Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.

A live, listen-only webcast will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the conference call live via telephone by pre-registering online using the following link, http://www.directeventreg.com/registration/event/3329959. Upon registration, a phone number, Direct Event Passcode and unique Registrant ID will be sent via email. This information will be needed in order to enter the conference call. Participants are advised to pre-register at least 10 minutes prior to joining the call.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005792/en/

FAQ

When will Geron Corporation release its financial results?

Geron Corporation will release its fourth quarter and full year 2020 financial results on March 11, 2021.

What are the key clinical trials that Geron is conducting?

Geron is conducting two Phase 3 clinical trials: IMerge for lower-risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

What time is the Geron conference call scheduled?

The conference call is scheduled for March 11, 2021, at 4:30 p.m. ET.

How can I access the Geron Corporation conference call?

Participants can access the conference call by pre-registering through a provided link.

What is the primary focus of Geron Corporation?

Geron Corporation focuses on developing and commercializing imetelstat, a first-in-class telomerase inhibitor for hematologic malignancies.